Is NRX Pharmaceuticals, Inc. (NRXPW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 180.1% / 33% | 39.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 180.1% / 33% | 39.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 58.8% | |
| Operating Margin | -467.3% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -121.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Total Debt | $7M |
| Current Ratio | 0.3 |
| Total Assets | $4M |
Price & Trading
| Last Close | $0.01 |
| Beta | 2.0 |
|
52-Week Range
$0.01
| |
About NRX Pharmaceuticals, Inc. (NRXPW)
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Related Halal Stocks in
Frequently Asked Questions
Is NRX Pharmaceuticals, Inc. (NRXPW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NRX Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NRX Pharmaceuticals, Inc.'s debt ratio?
NRX Pharmaceuticals, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 180.1%.
What are NRX Pharmaceuticals, Inc.'s key financial metrics?
NRX Pharmaceuticals, Inc. has a market capitalization of N/A.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.